Scholar Rock Holding Corp - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
SRRK Nasdaq 2836 https://scholarrock.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Scholar Rock Holding Corp

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 15th, 2023 12:00 pm
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress - Mar 7th, 2023 12:00 pm
Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - Mar 1st, 2023 1:00 pm
Scholar Rock to Present at the Cowen 43rd Annual Health Care Conference - Feb 27th, 2023 1:00 pm
Shareholders in Scholar Rock Holding (NASDAQ:SRRK) have lost 43%, as stock drops 13% this past week - Feb 11th, 2023 12:23 pm
Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer - Feb 6th, 2023 1:00 pm
Scholar Rock Provides Corporate Update and Highlights Priorities for 2023 - Jan 9th, 2023 1:00 pm
Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare Conference - Jan 3rd, 2023 1:00 pm
Scholar Rock Holding Third Quarter 2022 Earnings: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021) - Nov 16th, 2022 11:04 am
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Nov 15th, 2022 1:00 pm
Scholar Rock Reports Third Quarter 2022 Financial Results and Highlights Business Progress - Nov 14th, 2022 1:00 pm
Recent Phase 1 DRAGON Data Show SRK-181 Continues to be Well Tolerated with Early Indications of Efficacy - Nov 10th, 2022 2:00 pm
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer - Nov 9th, 2022 1:00 pm
Scholar Rock to Participate in Upcoming Investor Conferences - Nov 8th, 2022 1:00 pm
New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA - Oct 22nd, 2022 11:00 am
Scholar Rock to Present Data from the Phase 1 DRAGON trial at the SITC 37th Annual Meeting - Oct 6th, 2022 12:00 pm
Scholar Rock to Present New 24-Month Data from Phase 2 TOPAZ Study at Two International Conferences: World Muscle Society Congress and International Scientific Congress on Spinal Muscular Atrophy - Oct 4th, 2022 12:00 pm
Scholar Rock Appoints Jay Backstrom, M.D., M.P.H., to be its Next Chief Executive Officer - Sep 20th, 2022 11:00 am
Analyst Builds Bullish Case For This Neuromuscular Company, Sees 200% Upside - Sep 19th, 2022 6:39 pm
Scholar Rock to Present at Upcoming ACCP Annual Meeting and World CB & CDx Summit - Sep 16th, 2022 12:30 pm